Nature Communications (Jan 2021)
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy
- Matthias Gromeier,
- Michael C. Brown,
- Gao Zhang,
- Xiang Lin,
- Yeqing Chen,
- Zhi Wei,
- Nike Beaubier,
- Hai Yan,
- Yiping He,
- Annick Desjardins,
- James E. Herndon,
- Frederick S. Varn,
- Roel G. Verhaak,
- Junfei Zhao,
- Dani P. Bolognesi,
- Allan H. Friedman,
- Henry S. Friedman,
- Frances McSherry,
- Andrea M. Muscat,
- Eric S. Lipp,
- Smita K. Nair,
- Mustafa Khasraw,
- Katherine B. Peters,
- Dina Randazzo,
- John H. Sampson,
- Roger E. McLendon,
- Darell D. Bigner,
- David M. Ashley
Affiliations
- Matthias Gromeier
- Department of Neurosurgery, Duke University Medical Center
- Michael C. Brown
- Department of Neurosurgery, Duke University Medical Center
- Gao Zhang
- Department of Neurosurgery, Duke University Medical Center
- Xiang Lin
- Department of Computer Science at the New Jersey Institute of Technology
- Yeqing Chen
- Department of Computer Science at the New Jersey Institute of Technology
- Zhi Wei
- Department of Computer Science at the New Jersey Institute of Technology
- Nike Beaubier
- Tempus Labs, Inc.
- Hai Yan
- The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center
- Yiping He
- The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center
- Annick Desjardins
- Department of Neurosurgery, Duke University Medical Center
- James E. Herndon
- The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center
- Frederick S. Varn
- The Jackson Laboratory for Genomic Medicine
- Roel G. Verhaak
- The Jackson Laboratory for Genomic Medicine
- Junfei Zhao
- Department of Systems Biology at Columbia University
- Dani P. Bolognesi
- Department of Surgery, Duke University Medical Center
- Allan H. Friedman
- Department of Neurosurgery, Duke University Medical Center
- Henry S. Friedman
- Department of Neurosurgery, Duke University Medical Center
- Frances McSherry
- Department of Biostatistics, Duke University Medical Center
- Andrea M. Muscat
- School of Medicine, Deakin University
- Eric S. Lipp
- Department of Neurosurgery, Duke University Medical Center
- Smita K. Nair
- Department of Surgery, Duke University Medical Center
- Mustafa Khasraw
- Department of Neurosurgery, Duke University Medical Center
- Katherine B. Peters
- Department of Neurosurgery, Duke University Medical Center
- Dina Randazzo
- Department of Neurosurgery, Duke University Medical Center
- John H. Sampson
- Department of Neurosurgery, Duke University Medical Center
- Roger E. McLendon
- The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center
- Darell D. Bigner
- Department of Neurosurgery, Duke University Medical Center
- David M. Ashley
- Department of Neurosurgery, Duke University Medical Center
- DOI
- https://doi.org/10.1038/s41467-020-20469-6
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 7
Abstract
Recurrent glioblastomas (rGBM) have dismal outcomes, but long-term survival has been observed in subsets of patients after immunotherapy. Here the authors report a positive association between low tumor mutation burden, inflammatory gene signatures, and survival after immunotherapy in rGBM patients.
